British drugs giant AstraZeneca on 19th May rejected a final takeover bid from US rival Pfizer worth $117 billion (85 billion euros), saying that the terms undervalued the company.
Pfizer on Sunday made an improved and final offer worth £69 billion, pitched at £55 per share, but added that it would not proceed without a recommendation from AstraZeneca's management.
Pfizer on Sunday made an improved and final offer worth £69 billion, pitched at £55 per share, but added that it would not proceed without a recommendation from AstraZeneca's management.
